Ziopharm Oncology completes enrollment of controlled IL-12 monotherapy expansion substudy
Ziopharm Oncology announced it rapidly completed enrollment and treated a total of 36 patients in less than six months in a substudy to expand a Phase 1 trial evaluating its Controlled IL-12 platform as a monotherapy for treatment of recurrent glioblastoma. The trial was over enrolled. February 11, 2019